References
- Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC, Withrow SJ. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005;12(12):1073–83. doi:10.1245/ASO.2005.01.011.
- Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14(10):2887–95. doi:10.1245/s10434-007-9483-8.
- Yahiro K, Matsumoto Y, Yamada H, Endo M, Setsu N, Fujiwara T, Nakagawa M, Kimura A, Shimada E, Okada S, et al. Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes. Cancer Immunol Immunother. 2020;69(5):745–58. doi:10.1007/s00262-020-02508-9.
- Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the children’s oncology group. J Clin Oncol. 2008;26(4):633–38. doi:10.1200/JCO.2008.14.0095.
- Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretière JM, Marie B, Larousserie F, Entz-Werlé N, De Pinieux G, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017;6(9):e1331193.
- Toda Y, Kohashi K, Yamada Y, Yoshimoto M, Ishihara S, Ito Y, Iwasaki T, Yamamoto H, Matsumoto Y, Nakashima Y, et al. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions. J Cancer Res Clin Oncol. 2020;146(10):2607–20. doi:10.1007/s00432-020-03242-6.
- Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D’Angelo S, Attia S, Riedel RF, Priebat DA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. The Lancet Oncology. 2017;18(11):1493–501. doi:10.1016/S1470-2045(17)30624-1.
- Pu F, Chen F, Zhang Z, Qing X, Lin H, Zhao L, Xia P, Shao Z. TIM-3 expression and its association with overall survival in primary osteosarcoma. Oncol Lett. 2019;18(5):5294–300.